Humana Inc. HUM SPX
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 11.8% over 5 years.
- Generates positive free cash flow.
CONS
- Earnings shrank at -24.9% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HUM Humana Inc. SPX | 305.42 | 32.56 | $36.67B | 1.16% | - | 6.28% | 11.77% | -24.91% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.73B | 13.36B | 13.36B | 13.80B | 14.01B | 13.69B | 12.88B | 13.76B | 13.53B | 13.28B | 13.19B | 14.28B | 14.26B | 14.21B | 14.17B | 16.11B | 16.25B | 16.24B | 16.30B | 18.93B | 19.08B | 20.07B | 20.67B | 20.64B | 20.70B | 23.97B | 23.66B | 22.80B | 26.74B | 26.75B | 26.42B | 29.61B | 29.54B | 29.40B | - | 32.11B | 32.39B | 32.65B | 32.52B | 39.65B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 573.00M | 695.00M | - | 547.00M | 683.00M | 949.00M | - | 1.74B | 1.10B | 858.00M | - | 760.00M | 862.00M | 961.00M | - | 847.00M | 1.11B | 868.00M | - | 1.07B | 2.44B | 1.82B | 1.22B | 1.24B | 628.00M | 1.29B | 1.22B | 1.17B | 1.72B | 1.44B | 1.21B | 1.24B | 1.14B | 728.00M | - | 1.85B | 898.00M | 302.00M | -865.00M | 1.79B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 160.00M | 157.00M | 168.00M | 146.00M | 193.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.69B | 741.00M | 134.00M | -1.01B | 1.59B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 406.00M | 179.00M | -86.00M | -249.00M | 395.00M |
| Net Income | 431.00M | 314.00M | 101.00M | 254.00M | 311.00M | 450.00M | -401.00M | 1.11B | 650.00M | 499.00M | 184.00M | 491.00M | 193.00M | 644.00M | 355.00M | 566.00M | 940.00M | 689.00M | 512.00M | 473.00M | 1.83B | 1.34B | 828.00M | 588.00M | 1.53B | 930.00M | 696.00M | 1.20B | 1.24B | 959.00M | 832.00M | 741.00M | 679.00M | 480.00M | - | 1.24B | 545.00M | 195.00M | -796.00M | 1.19B |
| Diluted EPS | 2.85 | 2.09 | 0.67 | 1.68 | 2.06 | 2.98 | -2.68 | 7.49 | 4.46 | 3.44 | 1.29 | 3.53 | 1.39 | 4.65 | 2.58 | 4.16 | 6.94 | 5.14 | 3.84 | 3.56 | 13.75 | 10.05 | 6.39 | 4.55 | 11.84 | 7.29 | 5.48 | 9.39 | 9.87 | 7.66 | 6.71 | 6.11 | 5.62 | 3.98 | -5.76 | 10.30 | 4.51 | 1.62 | - | 9.83 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.29B | 28.95B | 30.74B | 33.60B | 36.83B | 39.13B | 41.31B | 48.50B | 54.29B | 54.38B | 53.77B | 56.91B | 64.89B | 77.16B | 83.06B | 92.87B | 106.37B | 117.76B | 129.66B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 1.36B | 1.07B | 1.71B | 1.85B | 2.34B | 2.02B | 2.06B | 2.36B | 2.35B | 1.74B | 4.26B | 3.10B | 3.19B | 4.99B | 3.15B | 3.97B | 3.88B | 2.38B | 2.19B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 401.00M | 493.00M | 660.00M | 631.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.57B | 3.38B | 1.72B | 1.55B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 762.00M | 836.00M | 413.00M | 250.00M |
| Net Income | 833.68M | 647.15M | 1.04B | 1.10B | 1.42B | 1.22B | 1.23B | 1.15B | 1.28B | 614.00M | 2.45B | 1.68B | 2.71B | 3.37B | 2.93B | 2.81B | 2.49B | 1.21B | 1.19B |
| Diluted EPS | 4.91 | 3.83 | 6.15 | 6.47 | 8.46 | 7.47 | 7.73 | 7.36 | 8.44 | 4.07 | 16.81 | 12.16 | 20.10 | 25.31 | 22.67 | 22.08 | 20.00 | 9.98 | 9.84 |
Compounded Sales Growth
| 5 Years: | 11.77% |
| 1 Year: | 23.50% |
Compounded Profit Growth
| 5 Years: | -24.91% |
| 1 Year: | -4.60% |
Stock Price Performance
| 1 Year: | +33.08% |
| 6 Months: | +29.49% |
| 3 Months: | +61.11% |
| 1 Month: | +25.63% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 13.04B | 14.15B | 16.10B | 17.71B | 19.98B | 20.73B | 23.53B | 24.68B | 25.40B | 27.18B | 25.41B | 29.07B | 34.97B | - | 43.05B | 47.06B | 46.48B | 48.91B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cash & Equivalents | 1.74B | 2.04B | 1.97B | 1.61B | 1.67B | 1.38B | 1.31B | 1.14B | 1.94B | 2.57B | 3.88B | 4.04B | 2.34B | 4.05B | 4.67B | - | 5.06B | 4.69B | 2.22B | 4.20B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.67B | 2.04B | 2.70B | 3.27B |
| Total Liabilities | - | - | 8.58B | 8.38B | 9.18B | 9.64B | 11.13B | 11.42B | 13.88B | 14.33B | 14.71B | 17.34B | 15.25B | 17.04B | 21.24B | - | 27.68B | 30.75B | 30.03B | 31.17B |
| Current Liabilities | - | - | 5.18B | 5.26B | 5.74B | 6.06B | 6.38B | 6.32B | 7.47B | 8.15B | 7.82B | 9.41B | 10.08B | 10.93B | 13.39B | - | - | - | - | - |
| Long Term Debt | - | - | 1.94B | 1.68B | 1.67B | 1.66B | 2.61B | 2.60B | 3.83B | 3.79B | 3.79B | 4.77B | 4.38B | 4.97B | 6.06B | - | 7.93B | 10.21B | 11.14B | 12.37B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.13B | 11.66B | 11.72B | 12.37B |
| Total Equity | 3.05B | 4.03B | 4.46B | 5.78B | 6.92B | 8.06B | 8.85B | 9.32B | 9.65B | 10.35B | 10.69B | 9.84B | 10.16B | 12.04B | 13.73B | - | 15.31B | 16.26B | 16.38B | 17.66B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 198.67M | 198.69M | 198.72M | 198.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.22B | 982.31M | 1.42B | 2.24B | 2.08B | 1.92B | 1.72B | 1.62B | 868.00M | 1.94B | 4.05B | 2.17B | 5.28B | 5.64B | - | 4.59B | 3.98B | 2.97B | 921.00M |
| Investing Cash Flow | -1.85B | -498.32M | -1.86B | -1.81B | -1.36B | -1.97B | -1.18B | -63.00M | 320.00M | -1.36B | -2.94B | -3.09B | -1.28B | -3.06B | - | -1.01B | -3.49B | -2.95B | 2.27B |
| Financing Cash Flow | 921.28M | -554.02M | 80.00M | -371.00M | -1.02B | -29.00M | -702.00M | -758.00M | -552.00M | 732.00M | -945.00M | -785.00M | -2.29B | -1.96B | - | -1.91B | -856.00M | -2.49B | -1.22B |
| Capital Expenditure | -239.24M | -261.57M | -185.00M | -222.00M | -346.00M | -410.00M | -441.00M | -528.00M | -523.00M | -527.00M | -524.00M | -612.00M | -736.00M | -964.00M | - | -1.14B | -1.00B | -575.00M | -546.00M |
| Free Cash Flow | 985.02M | 720.74M | 1.24B | 2.02B | 1.73B | 1.51B | 1.27B | 1.09B | 345.00M | 1.41B | 3.53B | 1.56B | 4.55B | 4.67B | - | 3.45B | 2.98B | 2.39B | 375.00M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.67B | -367.00M | -2.47B | 1.98B |
| Share Buybacks | 27.41M | 106.07M | 23.00M | 108.00M | 541.00M | 518.00M | 531.00M | 872.00M | 385.00M | 104.00M | 3.37B | 1.09B | 1.07B | 1.82B | 79.00M | 2.10B | 1.57B | 817.00M | 151.00M |
| Dividends Paid | - | - | 0 | 0 | 82.00M | 165.00M | 168.00M | 172.00M | 172.00M | 177.00M | 220.00M | 265.00M | 291.00M | 323.00M | 354.00M | 392.00M | 431.00M | 431.00M | 430.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 5.4% | 3.7% | 5.6% | 5.5% | 6.4% | 5.2% | 5.0% | 4.9% | 4.3% | 3.2% | 7.9% | 5.4% | 4.9% | 6.5% | 3.8% | 4.3% | 3.6% | 2.0% | 1.7% |
| Net Margin % | 3.3% | 2.2% | 3.4% | 3.3% | 3.9% | 3.1% | 3.0% | 2.4% | 2.4% | 1.1% | 4.6% | 3.0% | 4.2% | 4.4% | 3.5% | 3.0% | 2.3% | 1.0% | 0.9% |
| ROE % | 20.7% | 14.5% | 18.0% | 15.9% | 17.6% | 13.8% | 13.2% | 11.9% | 12.3% | 5.7% | 24.9% | 16.6% | 22.5% | 24.5% | - | 18.3% | 15.3% | 7.4% | 6.7% |
| ROCE % | - | 13.7% | 19.2% | 17.9% | 20.1% | 14.8% | 14.3% | 14.7% | 14.2% | 9.9% | 24.0% | 20.2% | 17.6% | 23.1% | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Dodge & Cox Inc. | 9.48% | 11.38M | $3.48B |
| 2 | Blackrock Inc. | 8.49% | 10.20M | $3.11B |
| 3 | Vanguard Capital Management LLC | 6.53% | 7.84M | $2.39B |
| 4 | Vanguard Portfolio Management LLC | 4.84% | 5.81M | $1.77B |
| 5 | Pzena Investment Management LLC | 4.56% | 5.47M | $1.67B |
| 6 | State Street Corporation | 4.54% | 5.45M | $1.67B |
| 7 | Massachusetts Financial Services Co. | 3.73% | 4.48M | $1.37B |
| 8 | Sessa Capital IM, L.P. | 3.10% | 3.73M | $1.14B |
| 9 | Geode Capital Management, LLC | 2.77% | 3.33M | $1.02B |
| 10 | JPMORGAN CHASE & CO | 2.53% | 3.03M | $926.71M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HUM